Curemark

Executive Summary

Curemark is a private, clinical-stage biopharmaceutical company founded in 2003 and headquartered in Rye, New York. The company focuses on developing novel therapies for serious neurological disorders, particularly those involving neurotransmitter deficiencies. Its lead program, CM-AT, is a first-in-class, disorder-modifying therapy designed to address the underlying pathophysiology of Autism Spectrum Disorder (ASD). CM-AT targets the deficiency of the enzyme chymotrypsin, which is hypothesized to impair protein digestion and lead to neurotransmitter imbalances. By normalizing protein digestion, CM-AT aims to reduce core symptoms of ASD, including social and communication deficits. The company has conducted multiple clinical trials and is currently advancing CM-AT through late-stage development, with the potential to become the first FDA-approved therapy for the core symptoms of autism. Curemark's pipeline also includes preclinical programs for other neurological conditions, such as Parkinson's disease and schizophrenia, leveraging similar mechanisms of neurotransmitter modulation. The company operates in a high-need area with limited approved treatments for ASD, offering significant market potential if CM-AT receives regulatory approval. Given its private status, Curemark has historically been funded through private investments and grants. The upcoming clinical milestones for CM-AT are pivotal for the company's value inflection, and successful data could lead to partnerships, additional financing, or a potential IPO. However, the binary nature of late-stage trial results and the regulatory pathway introduce substantial risk.

Upcoming Catalysts (preview)

• Q3 2026CM-AT Phase 3 Top-Line Data Readout40% success
• Q1 2027Pre-NDA Meeting with FDA60% success
• Q4 2026Potential Strategic Partnership for Commercialization30% success